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SUMMARY AND CONCLUSIONS
The prevalent solid tumors in the western world can not be cured once the tumor has
outgrown beyond the stage of surgical resectability. Neither conventional chemotherapy
nor immunotherapy or hormonal manipulation can rescue patients with disseminated
cancer of the breast, lung, colon or advanced stage ovarian cancer. Cytotoxic drugs can
however reduce tumor volume when given in a standard dose. For various tumor types
the experimental base for the supposition that high-dose chemotherapy might give better
results, or even lead to cure is considerable. In the clinical situation the curative
possibilities of intensive chemotherapy combined with autologous or allogeneic bone
mrurow transplantation have been proven in hematological malignancies.
In the chapters of this thesis we have outlined the experience of intensive chemo-
therapy and autologous bone marrow transplantation (ABMT) in adult patients with
various solid tumor types treated in our oncology department.
In Chapter 1 the criteria for the use of ABMT have been formulated. Also the proce-
dures of bone marrow collection, cryopreservation and reinfusion are described. Special
attention is paid to the fact that bone marrow harvesting was performed wittr local
anesthesia with lidocain and analgesia with meperidine/diazepam on an outpatient basis
and that general anesthesia is not necessary. Complications and patient acceptance of
the harvesting procedure were evaluated.
We advocate the use of inadiated allogeneic blood products during the bone mzurow
harvesting procedure and in the ABMT period because of the risk of graft-versus-host-
disease.
The overwhelming problem of the clinical management of ABMT patients lies in the
supportive care that they require. In this thesis this problem has been analysed to some
extent, especially nutritional support, bleeding prophylaxis, incidence and effects of
herpes virus infection and infection prophylaxis were subjects of investigation.
Chapter 2 deals with the nutritional problems of ABMT patients. Despite intensive
counseling of dieticians, nurses and doctors, these patients were found to eat insuf-
ficiently, while their metabolic needs were increased. This resulted in an unacceptable
weight loss of almost 107o. Therefore, we conducted a prospective randomized study of
the efficacy of hyperalimentation. Hyperalimentation consisted of 3400 non-protein
Kcalories and 25 grams of nitrogen (equivalent to 148 grams of protein) per day and
was given either as lotal parenteral nutrition or as half enteral and half parenteral
nutrition. We concluded that both regimens were effective in maintaining body weight
and nitrogen balance. We noticed that in balance studies the administration of blood
products should not be omitted because they account for substantial additional intake of
nitrosen.
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Probably due to vomiting and dianhea the daily requirements of copper and zinc in
ABMT patients were increased. The patients fed by a combination of parenteral plus
enteral nutrition suffered less days with diarrhea and got better supplementation with
calcium, copper, magnesium and zinc than the patients fed by total parenteral nutrition.
Hyperalimentation caused a significant increase in creatinine clearance. This pheno-
menon required an increase in the dosage of all drugs with renal elimination (including
antibiotics) administered to patients during the hyperalimentation period.
In addition to the balance studies, serial measurements of serum albumin, transferrin
and prealbumin were performed during the ABMT period. In general these visceral
proteins are considered useful as nuEitional markers. Serum levels were decreased on
day 7 , 14 and 21, compared to the initial level on day 0. We found evidence that non-
nutritional factors influence the course of the serum levels of these proteins. Such
faclors may consist of dilution due to the inEavenously administered volume, trans-
capillary leakage of small proteins and altered protein metabolisme due to cytotoxic
drugs.
Chapter 3 deals with bleeding prophylaxis. Severe thrombocytopenia exists during a
15-20 days period starting approximately one week after ttre beginning of intensive
chemotherapy.
Allogeneic thrombocytes are most often used for bleeding prevention. However,
autologous plateles eliminate the risk of transfusion related viral disease, graft-versus-
host-disease and immune reactions. We studied the feasibility of bleeding prophylaxis
using autologous platelets cryopreserved prior to intensive chemotherapy. In nearly half
of the 43 patients the tlrombocytopenic period could be bridged with four donations of
their own plateles. In the other half of the patients either more than 4 transfusions were
required, or inaccessible veins or insufficient time for platelet aphereses precluded the
sole use of autologous thrombocytes.
No bleeding episodes occurred following the administration of prophylactic auto-
logous platelet transfusions, so in 0rat respect hey were as active as fresh single donor
allogeneic platelets. The one hour increment for allogenic thrombocytes twice was as
high as for aulologous thrombocytes, but the interval between transfusions in days was
the same. So most probably autologous platelets possess a longer in vivo life span than
allogeneic platelets.
The washing step for removal of the cryoprotectant of the autologous platelets can
be omitted without adversely affecting this bleeding prophylaxis capacity and also
without introducing immediate or late complications due to intravenous adminisradon
of the cryoprotectant (57o dimethyl sulfoxide).
The major problem in dre immediate posttransplant period is created by infectious
complications. From the experience with allogeneic bone marrow transplantation it
became apparent hat cytomegalovirus infection is a common cause of posttransplant
morbidity and mortality. In contrast, in our experience with autologous bone marrow
transplantation, cyt
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transplantation, cytomegalovirus infection is a seldom observed clinical complication
despite the fact that the virus is latent in half of the patients at the start of intensive
chemotherapy.
The incidence and effects of another herpes virus are described in Chapter 4. We
noticed that this virus, the herpes simples virus (HSV) is reactivated in more than 60Vo
of HSV seropositive patients approximately seven days after bone marrow reinfusion.
This is surprising because recipients of bone muurow transplantation are immuno-com-
promised. Half of the patients with culture-proven HSV infection showed a significant
rise in complement-fixing antibody titer. Primary HSV infections did not occur. Patients
with a HSV infection had significantly more days with fever than those without HSV
infection. We found no difference in speed of hematological recovery between these
two groups of patients as suggested by other investigators.
Although viral infections cause morbidity in ABMT patients, the more serious
threats are caused by bacterial and fungal infections during the period with profound
granulocytopenia. Both the length and the depth of this granulocytopenia determine the
infection risk. The majority of these infections is caused by gram-negative micro-
organisms originating from the gastro-intestinal Eact.
In Chapter 5 infection prevention by elimination of these micro-organisms by
selective decontamination of the gut was studied in ABMT patients. Three regimens
were evaluated consisting of polymyxin B combined with oral neomycin, or combined
with parenteral temocillin or with oral cotrimoxazole. All three regimens were effective
in decolonization of the gut and in preventing gram-negative bacterial infections. How-
ever, a shift has taken place towards gram-positive infections, especially towards viri-
dans streptococci and coagulase negative staphylococci. For the moment the problem
how to prevent effectively gram-positive bacterial and fungal infections remains
unsolved. In that respect more gain may be expected from the use of hematopoetic
growth factors to shorten the granulocytopenic period than from prophylaxis with local
and/or systemic antibiotics.
Whettrer the concept of high-dose chemotherapy is an effective approach in the
trealment of disseminated solid tumors is investigated in Chapters 6, 7 and 8. Most of
the experience was gained in previously treated patients who had relapsing or refractory
tumors. Occasionally this treatment modality was the initial therapy in hopeless cases.
The total cure rate or at least long{erm disease free survival is in over 50 patients in
these situations approximately ll%o. Although this result is not negligible, it should be
balanced against the toxicity of the treatment, especially against the chance of treatment
related death. In Chapter 6 the results of high-dose chemotherapy with cyclo-
phosphamide and etoposide followed by ABMT in patients with disseminated testicular
cancer are descibed. In general non-seminomateus germ cell tumors are chemosensitive
and with remission-induction chemotherapy a durable complete remission rate of ?07o
is reached. The patients treated in our study had failed remission-induction treatment
and showed bad prognostic signs (big tumor load, very high levels of tumor marker(s)).
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Only two out of eleven patients achieved a complete remission. It, was concluded that 2
courses of maximally tolerable doses of chemotherapy offer insufficient prospect to
long-term disease free survival. Nevertheless the cure rate of 20Vo is uncommon
compared to any other regimen in this stage of disease.
More promising results were obtained with high-dose chemotherapy and ABMT in
eleven patients with advanced epithelial ovarian cancer, refractory to prior chemo-
ttrerapy and debulking surgery (Chapter 7). Six complete remissions were achieved in
patients with residual tumor smaller than 2 cm. Two of these patients have now a
disease free survival of4+ respectively 6+ years. The experience with the treatrnent of
patients with locally advanced or disseminated breast cancer described in Chapter 8 also
supports the concept that high-dose chemotherapy may have a curative potential but that
it should be applied in patients with limited tumor load. These 18 patients with breast
cancer were treated with the intensification regimen after they were rendered disease
free by 6 prior courses of remission-induction chemotherapy with adriamycin, 5-fluoro-
uracil, methoEexate, vincristine and prednisone. To date, 24 patients with breast cancer
have been treated that way with presently disease free survival in l3 patients.
To extent the scope of intensive treatment in solid tumors, new treatment combinations
have to be defined. Two new cytostatic agents of interest for study in intensive chemo-
therapy regimens are miloxantrone, an antracenedione derivative and carboplatin, a
cisplatin analogue. Pharmacokinetic studies of new drugs are important to investigate
the optimal moment for bone muurow reinfusion, because miurow stem cells should not
be exposed to cytotoxic drug concentrations. The pharmacokinetic behavior of mito-
xantrone and of carboplatin is described in respectively Chapter 9 and 10. We conducted
a phase I rial with escalating doses of mitoxantrone plus cyclophosphamide. This
combination was not feasible because of unexpected haemorrhagic cystitis. Therefore
cyclophosphamide was replaced by melphalan. The maximally tolerable dose of mito-
xantrone in combination with high-dose melphalan appeared to be 60 mg/m2. Dose-
limiting toxicity was mucositis of the oropharyngeal region.
High-dose carboplatin (750 mg/mz) was given as part of an ablative regimen to
patients with testicular or ovarian cancer, who had been pretreated with cisplatin and
who had a subnormal renal function. Carboplatin is less nephrotoxic than cisplatin
because it has less (cell) protein binding and because the renal elimination of the drug is
by glomerular filnation and in contrast to cisplatin not by tubular secretion. Never-
ttreless we observed one patient with impaired renal function who developed frank renal
failure and signs of tubular damage during carboplatin treatment.
We conclude that high-dose chemotherapy with autologous bone m,urow rescue offers
response rates in various solid tumors as ovarian cancer, breast cancer and testicular
cancer that. are superior to the best available results with conventional therapy in
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Breast cancer and ovarian cancer and possibly testicular cancer should be studiedfurther as indications for this treatment strategy. We will continue the study with the
cyclophosphamide plus etoposide regimen in breast cancer. For ovarian cancer a new
regimen has been developed as described in this ttresis, consisting of mitoxantrone and
melphalan.
In the future, the applicability of carboplatin should deserve serious consideration.
The renal function in patients previously fteated with cisplatin should however be an
area of concern.
Improvement on the current results of high-dose chemotherapy followed by ABMT
can probably be reached by using it as a consolidation at the time of limited tumor load,by the use of new active drugs in ablative regimens and by apprication of post-intensification radiotherapy or appropriately timed surgery. ntso ne cnnical benefits ofthe use of hema[opoetic growth factors should be investigated because reduction of theperiod of severe granulocytopenia may lead to decreased morbidity and mortality.
These further improvements are critically dependent on clinical research facilities
for this form of developmental medicine.
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